生物标志物与抗肿瘤药物研发
|
摘要
肿瘤患者广泛存在着个体之间的差异以及个体的肿瘤组织内部差异,需要通过生物标志物来区分和确定对药物具不同响应的个体。因此,生物标志物在抗肿瘤药物研发中起着重要的作用。
引文
[1]Nattestad M,Goodwin S,Karen N,et al.Complex rearrangements and oncogene amplifications revealed by long-read DNA and RNAsequencing of a breast cancer cell line.Genome Res,2018,28:1126-1135.
[2]Findlay G M,Daza R M,Martin B,et al.Accurate functional classification of thousands of BRCA1 variants with saturation genome editing.Nature,2018,562:217-222.
[3]Presley C J,Tang D,Soulos P R,et al.Association of broad-based genomic sequencing with survival among patients with advanced nonsmall cell lung cancer in the community oncology setting.JAMA,2018,320:469-477.
[4]Heitzer E,Haque I S,Roberts C E S,et al.Current and future perspectives of liquid biopsies in genomics-driven oncology.Nat Rev Genet,2019,20:71-88.
[5]Merker J D,Oxnard G R,Compton C,et al.Circulating tumor DNAanalysis in patients with cancer:American Society of Clinical Oncology and College of American Pathologists joint review.J Clin Oncol,2018,36:1631-1641.
[6]Kim Y,Jeon J,Mejia S,et al.Targeted proteomics identifies liquidbiopsy signatures for extracapsular prostate cancer.Nat Communi,2016,7:11906.
[7]Zhang B,Wang J,Wang X J,et al.Proteogenomic characterization of human colon and rectal cancer.Nature,2014:513:382-387.
[8]Shen S Y,Singhania R,Fehringer G,et al.Sensitive tumour detection and classification using plasma cell-free DNA methylomes.Nature,2018,563:579-583.
[9]Hoadley K A,Yau C,Hinoue T,et al.Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer.Cell,2018,173:291-304.
[10]Ma X T,Liu Y,Liu Y L,et al.Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.Nature,2018,555:371-376.
[11]Berger A C,Korkut A,Kanchi R S,et al.A comprehensive pan-cancer molecular study of gynecologic and breast cancers.Cancer Cell,2018,33:690-705.
[2]Findlay G M,Daza R M,Martin B,et al.Accurate functional classification of thousands of BRCA1 variants with saturation genome editing.Nature,2018,562:217-222.
[3]Presley C J,Tang D,Soulos P R,et al.Association of broad-based genomic sequencing with survival among patients with advanced nonsmall cell lung cancer in the community oncology setting.JAMA,2018,320:469-477.
[4]Heitzer E,Haque I S,Roberts C E S,et al.Current and future perspectives of liquid biopsies in genomics-driven oncology.Nat Rev Genet,2019,20:71-88.
[5]Merker J D,Oxnard G R,Compton C,et al.Circulating tumor DNAanalysis in patients with cancer:American Society of Clinical Oncology and College of American Pathologists joint review.J Clin Oncol,2018,36:1631-1641.
[6]Kim Y,Jeon J,Mejia S,et al.Targeted proteomics identifies liquidbiopsy signatures for extracapsular prostate cancer.Nat Communi,2016,7:11906.
[7]Zhang B,Wang J,Wang X J,et al.Proteogenomic characterization of human colon and rectal cancer.Nature,2014:513:382-387.
[8]Shen S Y,Singhania R,Fehringer G,et al.Sensitive tumour detection and classification using plasma cell-free DNA methylomes.Nature,2018,563:579-583.
[9]Hoadley K A,Yau C,Hinoue T,et al.Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer.Cell,2018,173:291-304.
[10]Ma X T,Liu Y,Liu Y L,et al.Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.Nature,2018,555:371-376.
[11]Berger A C,Korkut A,Kanchi R S,et al.A comprehensive pan-cancer molecular study of gynecologic and breast cancers.Cancer Cell,2018,33:690-705.